ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM
Abstract Number: 2736
Reduction of Disease Burden on Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III
9:00AM-11:00AM
Abstract Number: 2569
Regulation of SIRT1 Maybe a Perfect Strategy in Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis - Animal Models Poster
9:00AM-11:00AM
Abstract Number: 2389
Relation of Pronated Foot Posture to Risk of Worsening Knee Pain during Gait and Compartment-Specific Knee Cartilage Damage
Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research
9:00AM-11:00AM
Abstract Number: 2305
Relationship Between Anxiety, Depression, Sleep, Fibromyalgia and BMI in Patients with Rheumatic Disease
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II
9:00AM-11:00AM
Abstract Number: 2780
Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III
9:00AM-11:00AM
Abstract Number: 2883
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy
9:00AM-11:00AM
Abstract Number: 2593
Relationship Between Index of Activity Speed (Time Up and Go test) and Patient-Reported Outcome in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function
Rheumatoid Arthritis - Clinical Aspects Poster Session III
9:00AM-11:00AM
Abstract Number: 2307
Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II
9:00AM-11:00AM
Abstract Number: 2868
Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy
9:00AM-11:00AM
Abstract Number: 2961
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III
9:00AM-11:00AM
Abstract Number: 2410
Report from the International Consortium of Health Outcome Measurement Hip and Knee Osteoarthritis Working Group: Consensus on an International Standard Set of Outcomes Measures for Patients with Hip or Knee Osteoarthritis.
Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research
9:00AM-11:00AM
Abstract Number: 2544
Representing the Variability in Patients’ Preferences
Research Methodology Poster (ARHP)
9:00AM-11:00AM
Abstract Number: 2227
Resident’s Guide to Pediatric Rheumatology Mobile App: Assessing Enablers and Barriers of Use through Qualitative Focus Groups
Education Poster II
9:00AM-11:00AM
Abstract Number: 2308
Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II
9:00AM-11:00AM
Abstract Number: 2313
Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences
  • «Previous Page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • …
  • 72
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology